Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Sun Pharma Announces U.S. FDA Approval of ILUMYA™

Posted On: 2018-03-21 07:07:19

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies) today announced that the U.S. Food and Drug Administration (FDA) has approved ILUMYA™ (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ILUMYA™ selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor leading to inhibition of the release of pro-inflammatory cytokines and chemokines. ILUMYA™ is administered at a dose of 100 mg by subcutaneous injection every 12 weeks, after the completion of initial doses at weeks 0 and 4. ILUMYA™ is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients.

"With the approval of ILUMYA™ and our long-standing commitment in dermatology, we are focused on making a difference for people living with moderate-to-severe plaque psoriasis," said Abhay Gandhi, President and Chief Executive Officer, North America, Sun Pharma. "We are committed to working with all relevant stakeholders to make ILUMYA™ available to appropriate people with plaque psoriasis."

The FDA approval of ILUMYA™ for the treatment of adults with moderate-to-severe plaque psoriasis was supported by data from the pivotal Phase-3 reSURFACE clinical development program. In the two multicenter, randomized, double-blind, placebo-controlled trials (reSURFACE 1 and reSURFACE 2), 926 adult patients were treated with ILUMYA™ (N=616) or placebo (N=310). Results from these studies were published in The Lancet in July 2017, with primary endpoints presented at the 25th European Academy of Dermatology and Venereology (EADV) Congress.

Both Phase-3 studies met the primary efficacy endpoints, demonstrating significant clinical improvement with ILUMYA™ 100 mg compared to placebo when measured by at least 75 percent of skin clearance (Psoriasis Area Sensitivity Index or PASI 75) and Physician's Global Assessment (PGA) score of "clear" or "minimal" at week 12 after two doses.

Of the patients in the reSURFACE 1 study 74 percent (229 patients) achieved 75 percent skin clearance at week 28 after three doses, and 84 percent of patients who continued receiving ILUMYA™ 100 mg maintained PASI 75 at week 64 compared to 22 percent of patients who were re-randomized to placebo. In addition, 69 percent of the patients receiving ILUMYA™ 100 mg who had a PGA score of "clear" or "minimal" at week 28 maintained this response at week 64 compared to 14 percent of patients who were re-randomized to placebo.

Shares of SUN PHARMACEUTICAL INDUSTRIES LTD. was last trading in BSE at Rs.504.7 as compared to the previous close of Rs. 508.85. The total number of shares traded during the day was 409209 in over 3190 trades.

The stock hit an intraday high of Rs. 515.8 and intraday low of 502.8. The net turnover during the day was Rs. 208634257.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Pointer Telocation and Pricol sign LOI to form a JV for Telematics Solutions in India and South East Asia

Wipro Achieves 'Cloud Elite' status in Oracle PartnerNetwork Cloud Program

Jubilant FoodWorks allotted 51 lakh shares in Bangladesh JV

Music Broadcast Ltd board to consider stock split

TCS Recognized as a Leader in Gartner Magic Quadrant for Application Testing Services, WW

Ambuja Cements Ltd approves expansion plan of 1.4 MT additional clinker capacity

TVS Motor Company wins 2 key awards at CII - ITC Sustainability Awards 2018

Tribhovandas Bhimji Zaveri Ltd to shift Ghatkopar showroom

Mr. Ajay Kapur, MD& CEO of Ambuja Cements Ltd resigns

AGIO Paper & Industries Ltd approves fund raising of Rs. 5 crores

IL&FS Transportation Networks Ltd gets provisional completion certificate for project in Jharkhand

Ramco Systems continues to strengthen foothold in the U.S. Defense space

Amrutanjan Health Care bags award

TCS Scores a Gold in the EcoVadis CSR Assessment for Fifth Year in a Row

McDonald's expands its footprint in Kerala with its first outlet in Thiruvananthapuram

Tata Communications discovers digital transformation disparity in new study

Premier Chennai Properties Ltd appoints Non-Executive Independent Director

ICRA revises rating of Remsons Industries Ltd

CRISIL Ratings on the bank facilities of Krypton Industries Limited

Strides Vivimed Labs JV receives approval for Albendazole Tablets

SVP Global Ventures Ltd updates on Oman Unit

ACC Ltd announces expansion proposals of Rs. 3000 crore

Honeywell Automation India Wins Golden Peacock Award For Corporate Ethics

NBCC India Ltd receives LoA for Rs. 172 crores project

Sterlite Tech strengthens technology leadership with two crucial appointments

City Union Bank Ltd opens new branch at Katargam, Surat

Finolex Cables Ltd appoints Miss. Poornima K Prabhu as director

Larsen & Toubro Infotech Ltd appoints Nachiket Deshpande as Chief Operating Officer

Ashok Leyland and Israel's ELBIT Systems sign MOU for High Mobility Vehicles

Liva Pharmaceuticals receives approval from the USFDA for its sANDA, Ranitidine Injection USP

Zydus Wellness' acquisition of Heinz India receives a nod from Competition Regulator

Kaveri Seed Company Ltd to consider merger of subsidiaries

PNC Infratech Ltd arm executes financing documents to NHAI

PFC board takes note of acquisition of stake in REC

CARE reaffirms ratings of Shree Cement Ltd

Industrial Investment Trust Ltd Q2 FY19 standalone loss at Rs. 1.45 crore

Shalby signs MOU with International SOS for providing Medical Assistance to Foreign Travellers to India

DIC India Ltd announces resignation of MD & CEO

PTron launches Spunk - the pocket friendly smart true wireless stereo earbuds

Wipro Launches Automotive Innovation Center in Detroit, Michigan

Reliance Industries Ltd allots 25000 NCDs

Shalby Academy signs MOU with Ahmedabad Institute of Medical Sciences

CRISIL revises rating outlook of Titan Company Ltd

TCS Named a Leader in Capital Markets BPO Services by Everest Group for Sixth Consecutive Year

POWERGRID enters in term Loan facility with Sumitomo Mitsui Banking Corporation, Singapore Branch

Aurobindo Pharma subsidiary to form JV in China

United Bank of India board to consider raising capital

Mindtree.org Launches Social Inclusion Platform to Democratize Technology for Micro-Entrepreneurs

Parag Milk Foods Limited launches 'Avvatar Advanced Mass Gainer'

Sundaram Clayton Ltd Fixes Feb 2, 2019 as Record Date for Interim Dividend







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2018